The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic value of PSMA PET against CHAARTED criteria in an ENZAMET sub-cohort.
 
Zahra Sabahi
No Relationships to Disclose
 
Nathan Papa
No Relationships to Disclose
 
Wolfgang Fendler
Honoraria - Parexel
Consulting or Advisory Role - Calyx; GE Healthcare; Janssen; Lilly
Speakers' Bureau - ABX Advanced biochemical compounds; Amgen; Bayer; Eczacibasi Monrol; GE Healthcare; Janssen; Novartis; Telix Pharmaceuticals
Research Funding - SOFIE
 
Andrew Nguyen
No Relationships to Disclose
 
Keith Wong
No Relationships to Disclose
 
Narjess Ayati
No Relationships to Disclose
 
Bao Ho
No Relationships to Disclose
 
Jeffrey Chen
No Relationships to Disclose
 
Thomas Cusick
No Relationships to Disclose
 
Irene Burger
No Relationships to Disclose
 
Megan Crumbaker
Honoraria - Bayer; Merck
Consulting or Advisory Role - Astellas Pharma; Pfizer
Travel, Accommodations, Expenses - MSD Oncology
 
Gavin Marx
Consulting or Advisory Role - Astellas Pharma
Travel, Accommodations, Expenses - Astellas Pharma
 
Shikha Sharma
No Relationships to Disclose
 
Mark Frydenberg
Leadership - Genesis Cancer Care
Stock and Other Ownership Interests - Telix Pharmaceuticals (I)
 
Shahneen Sandhu
Honoraria - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Skyline Diagnostics (Inst)
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); Bristol Myers Squibb (Inst); Merck Sharp and Dohme (Inst); Novartis (Inst); Roche/Genentech (Inst); Skyline Diagnostics (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Senhwa Biosciences (Inst)
(OPTIONAL) Uncompensated Relationships - AAA/Endocyte/Novartis (Inst)
 
Ian Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); ESSA (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
(OPTIONAL) Uncompensated Relationships - ANZUP Cancer Trials Group
 
Martin Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Tilray (Inst)
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Cadence Pharma; CellCentric; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; POINT Biopharma
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Anthony Joshua
Stock and Other Ownership Interests - Pricilium Therapeutics
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Grey Wolf Therapeutics (Inst); IDEAYA Biosciences (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Mayne Pharma (Inst); Medison (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Starpharma (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Genentech (Inst); Immunocore (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Myeloid Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Cancer therapeutic methods; Use of Darovasertib for Neoadjuvant treatment ocular Melanoma
 
Louise Emmett
Consulting or Advisory Role - Advancell; Astellas Pharma; Clarity Pharmaceuticals; Novartis
Speakers' Bureau - Astellas Pharma (Inst); Janssen Oncology; mundipharma; Novartis
Research Funding - Clarity Pharma (Inst); Novartis (Inst); PCF (Inst)
Travel, Accommodations, Expenses - Advancell
 
The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
No Relationships to Disclose